Not All CSTDs

Are Created Equal

Not All CSTDs Are Created Equal

About Closed System Transfer Devices (CSTDs)

Definition and purpose of CSTDs

According to the National Institute for Occupational Safety and Health (NIOSH), a CSTD is a drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drugs or vapors outside of the system1. These devices serve as a critical tool to prevent exposure to hazardous drugs, which can cause serious health effects in healthcare workers. The use of CSTDs has been mandated in several countries worldwide, including the United States, due to the high incidence of hazardous drug exposure among healthcare workers. The EU and the UK strongly recommend their use and are moving towards mandatory regulation.

Why are CSTDs so important?

Hazardous drugs, or hazardous medicinal products such as chemotherapy agents, antiviral medications, and immunosuppressive drugs pose significant health risks to medical personnel who handle them. These risks include skin irritation, allergic reactions, reproductive issues, and even the development of cancer.2 To minimize exposure to hazardous drugs and ensure the long-term health and safety of medical personnel, it is essential to implement best practices and safety measures.

Differentiation of CSTDs

Evaluating the CSTDs solutions on the market

Clinical Backing

Clinical Backing

Evidence Based Solutions

EQUASHIELD® products are supported by an ever- growing body of clinical evidence.

Plunger Rod Contamination

Studies consistently demonstrate elimination of plunger rod contamination with EQUASHIELD® CSTD. Designed with a patented closed-back system, these devices prevent environmental contamination while safeguarding medication integrity. Study 1, Study 2, Study 3, Study 4
Click Here

Surface Contamination

Studies have revealed significant surface contamination in Isolators, BSCs, pharmacies, and healthcare environments that do not utilize EQUASHIELD® CSTD. Wipe sampling consistently demonstrates undetectable levels of surface contamination when EQUASHIELD® CSTD are implemented. Study 1
Click Here

Vapor Containment

EQUASHIELD's® patented closed-back, fully encapsulated design is tested to contain all vapors without any emission, and be air tight, setting it apart from competitors. Study 1, Study 2, Study 3, Study 4
Click Here

Microbial Ingress

The EQUASHIELD® CSTD ensures no contaminants are coming into the system. This minimizes microbial contamination and has been tested to maintain medication integrity and is FDA- cleared for 10 withdrawals for up to 7 days. Study 1, Study 2
Click Here

Leak Proof

Clinical studies have consistently proven the outstanding connector integrity and leakproof performance of the EQUASHIELD® CSTD, ensuring reliable protection against exposure to hazardous drugs. Study 1, Study 2, Study 3, Study 4
Click Here

Efficiency

Clinical studies demonstrate that EQUASHIELD® requires fewer steps and less time compared to other CSTD competitors for compounding and administering Study 1, Study 2
Click Here

Regulatory Clearance

Regulatory Clearance

Comply With International Regulation And Best Practices

The FDA ONB code ensures rigorous evaluation and regulation of CSTD for safety and efficacy. It standardizes device classification, streamlines oversight, supports compliance, and enhances healthcare worker safety in handling hazardous drugs. EQUASHIELD® is cleared under FDA 510(k) clearance: K221513 Product Code: ONB Classification Name: Closed Antineoplastic And Hazardous Drug Reconstitution And Transfer System.

The CE Mark plays a critical role in ensuring that medical devices, including Closed System Transfer Devices (CSTD), meet the required health, safety, and environmental protection standards within the European Economic Area (EEA). By achieving CE Mark certification, CSTD demonstrate compliance with relevant directives and regulations, such as the European Medical Device Regulation (MDR). EQUASHIELD® is certified the CE mark under the Medical Device Regulation 2017/745.

The National Institute for Occupational Safety and Health (NIOSH) sets guidelines in the United States requiring the use of CSTD to safeguard healthcare workers from exposure to hazardous drugs. NIOSH defines CSTD as an engineering control that mechanically prohibit the transfer of environmental contaminants into the system and prevent the escape of hazardous drug vapors, aerosols, and liquids. The EQUASHIELD® CSTD effectively meets this definition.
European Directive 431 are guidelines focusing on protecting workers in the EU from exposure to harmful chemicals, including hazardous drugs, by encouraging strong safety measures like CSTDs in healthcare settings. As of 2022 the directive focuses on the classification, labeling, and regulation of carcinogenic, mutagenic, or reprotoxic (CMR) substances. 

The CMR guidelines prioritize worker safety by minimizing exposure to carcinogenic, mutagenic, or reprotoxic substances. They advocate for strict controls, like CSTD, to contain and reduce contamination risks.

Comply with International
Regulation and Best Practices

Technology

Technology

Connector Technology

Connector technology plays a key role in ensuring both leak-proof performance and airtight reliability.3,4

Luer Based CSTD

Luer systems such as those with an additional valve on the market today are leaky systems as shown by independent and peer reviewed studies. Although they are needle free, they still may leak and are less effective when used with HDs.

Membrane Based CSTD

Membrane based systems are typically better at leakage prevention. Testing data consistently highlights EQUASHIELD® as a top performer among membrane-based solutions, effectively preventing microbial ingress.5

Pressure Equalization

The technology used for pressure equalization contributes to the ability of CSTD to be air tight.6

Filter Based

Filter Based Systems use either a charcoal and/or 0.2 micron filter to equalize pressure with the environment. Filter based technologies aren’t mechanically closed or air tight.

Barrier System | Balloon

Balloon Based Technologies build a pressure equalization chamber in the external dome/bladder/balloon. These systems add an additional step to compounding.

Barrier System | Full encapsulation

Full Encapsulation Technology is defined as a no external balloons or environment to equalize pressure. The closed back dual needle encapsulated design achieves built in pressure equalization requiring no additional steps.

The Only Closed Back Syringe Unit On The Market

Standard syringes release aerosols and vapor, and may leak or spill. If you use traditional technology, exposure to hazardous drugs is inevitable.

Hazards

EQUASHIELD® Solution

/ Syringe Barrel Contamination

Syringe barrel contamination compromises the integrity of the medication and the safety of the patient.

/ Syringe Barrel Contamination Prevention

Fully encapsulated Syringe Units prevent the exposure to syringe barrel contamination.

/ Vapor Escape

Vapor escape in healthcare settings can result in the inhalation of aerosolized drugs and environmental contamination, posing significant health risks to medical personnel who handle them. These risks include skin irritation, allergic reactions, reproductive issues, and even the development of cancer.

/ Airtight Vapor Containment

EQUASHIELD® Syringe Units maintain a closed pressure equalization that prevent the escape of vapors and aerosols during compounding and administration.

/ Plunger Rod Contamination

Plunger Rod Contamination exposes healthcare workers to hazardous drugs upon coming into contact with the contaminated plunger rod during handling.

/ Plunger Rod Contamination Prevention

The closed back protects from plunger rod contamination and from the back of the syringe. Significant contamination levels were detected on syringe plungers of CSTD competitors whereas all EQUASHIELD® syringes remained uncontaminated.6

/ Accidental Disconnections and Needle Sticks

Accidental disconnections and needle stick injuries pose significant risks in oncology healthcare and cleanroom environments, potentially leading to hazardous spills and direct exposure to dangerous substances.

/ Pre-Bonded Components are Safer

The connector is permanently bonded onto the syringe body   housing the shielded needles to prevent the risk of accidental needle sticks. This, combined with locking connectors prevents accidental disconnects in preparation and administration.

/ Inefficient Syringe Usage

Most CSTDs utilize standard syringes and limit the fill volume to three-quarters when handling hazardous drugs (as recommended by OSHA and ASHP). This precaution is in place to prevent plunger disconnection. This restriction results in increased waste, added workload, longer administration times, and higher overall costs.

/ Full Volume Use

FDA cleared to use the full volume of the syringe unit.7  This is due to the encapsulated plunger which cannot be detached from the barrel, ensuring the safe usage of the entire Syringe Unit volume. Benefit from cost savings, reduced strain, time savings, and waste reduction.

Ergonomics

Ergonomics

EQUASHIELD CSTDs are designed with the user in mind.

EQUASHIELD® CSTD Are Designed With The User In Mind

Designed with ergonomic features like comfortable grips and contours that naturally fit in healthcare providers hand. Simple sliding motion to lock.

Holding it in your hands feels solid and secure, offering reliability unlike other solutions. Its design ensures it stays firmly connected, making accidental disconnection virtually impossible.

Low strain vs high strain means lower potential for repetitive stress injury. Fewer steps to compound and administer minimizes repetitive motions and risk for developing joint pain or carpal tunnel syndrome.

EQUASHIELD® requires 12 steps to compound, the fewest of CSTD competitors.8 EQUASHIELD® has lowest average time  for administering compared to other CSTD solutions.9

Built in pressure equalization means fewer steps to compound compared to balloon CSTDs.

Unique locking mechanism with red-to-red markings for fail proof connections. Locking mechnasim prevents accidental disconnects.

EQUASHIELD® Leads the CSTD Market

The only FDA cleared CSTD for full volume use

CSTD sizes Equashield

Safe, Simple, and Closed

EQUASHIELD is engineered to be the safest and most closed option on the market. A leader in pharmacy in the US,  its proprietary design makes it faster and more user-friendly compared to other CSTDs.10

Talk to our experts

With decades of clinical experience, the EQUASHIELD mission is to protect healthcare teams from hazardous drugs. We understand your needs and speak your language in order to ensure seamless integration. Let’s talk!

Talk to our experts

With decades of clinical experience, the EQUASHIELD mission is to protect healthcare teams from hazardous drugs. We understand your needs and speak your language in order to ensure seamless integration. Let’s talk!

References:

  1. National Institute for Occupational Safety and Health (NIOSH), Closed System Drug-Transfer Device (CSTD) Research – Centers for Disease Control and Prevention, https://www.cdc.gov/niosh/healthcare/hazardous-drugs/cstd-research.html#:~:text=Overview,concentrations%20outside%20the%20system%22%201
  2. NIOSH Alert Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Healthcare Settings, September 2004 – Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, https://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf
  3. Comparing the Efficiency of Closed System Transfer Devices for Compounding Pharmacy Practice & Products – Fouzia Berdi, United States, 2015. https://www.equashield.com/clinical-studies/comparing-the-efficiency-of-closed-system-transfer-devices-for-compounding/
  4. Effectiveness of Closed System Drug Transfer Devices in Reducing Leakage during Antineoplastic Drugs Compounding – Maria Teresa Piccardo, Alessandra Forlani, and Alberto Izzotti, International Journal of Environmental Research and Public Health, 2015.
  5. Connector Integrity Testing to Assess the Efficacy of Multiple Closed System Transfer Devices – University of North Carolina; Shawn O. StreeterÂą, Charlotte M. ForshayÂą, Stephanie A. SalchÂą, Stephen F. Eckel, PharmD, MHA, BCPSÂą,², North Carolina, United States, 2016. https://www.equashield.com/clinical-studies/connector-integrity-testing-to-assess-the-efficacy-of-multiple-closed-system-transfer-devices/
  6. Syringe Plunger Contamination by Hazardous Drugs: A Comparative Study – Stephen T. Smith and Mark C. Szlaczky, Journal of Oncology Pharmacy Practice, Karmanos Cancer Center, Detroit, USA, 2015. https://www.equashield.com/clinical-studies/syringe-plunger-contamination-by-hazardous-drugs-a-comparative-study/
  7. FDA Clearance of EQUASHIELD® Syringe Unit for Full Volume Use – EQUASHIELD, October, 2023. https://www.equashield.com/articles/fda-clearance-of-equashield-syringe-unit-for-full-volume-use/
  8. Berdi, F. (2015). Comparing The Efficiency of Closed System Transfer Devices for Compounding Pharmacy Practice & Products. (https://www.equashield.com/clinical-studies/comparing-the-efficiency-of-closed-system-transfer-devices-for-compounding/)
  9. Kicenuik, K., Northrup, N., Dawson, A., Locke, J., Villamil, J. A., Chretin, J., Sfiligoi, G., Clifford, C., Rosenberg, M., Hamilton, T., Regan, R., ParsonsDoherty, M., Mallett, C., Philibert, J., Impellizeri, J., & Hofmeister, E. (2015). Treatment Time, Ease of Use, and Cost Associated With the Use of Equashield™, PhaSeal®, or No Closed System Transfer Device for Administration of Cancer Chemotherapy to a Dog Model. University of Georgia, USA. Retrieved from https://www.equashield.com/clinical-studies/equashield-phaseal-no-cstd-for-administration-of-cancer-chemotherapy-to-dog-model/
  10. Application of the 2015 Proposed NIOSH Vapor Containment Performance Protocol for Closed System Transfer Devices Used During Pharmacy Compounding and Administration of Hazardous Drugs – University of North Carolina, Charlotte; M. Forshay, Shawn O. Streeter, Stephanie A. Salch, and Stephen F. Eckel, North Carolina, United States, 2018. https://www.equashield.com/clinical-studies/application-of-the-2015-proposed-niosh-vapor-containment-performance-protocol-for-closed-system-transfer-devices-used-during-pharmacy-compounding-and-administration-of-hazardous-drugs/